Amedisys Inc (NASDAQ:AMED)‘s stock had its “hold” rating reiterated by research analysts at Royal Bank Of Canada in a report released on Monday.

A number of other analysts have also weighed in on the stock. Mizuho lowered shares of Amedisys from a “buy” rating to a “neutral” rating and set a $50.00 price objective for the company. in a research note on Wednesday, July 26th. SunTrust Banks, Inc. restated a “buy” rating and set a $60.00 price objective on shares of Amedisys in a research note on Monday, October 9th. Oppenheimer Holdings, Inc. restated a “buy” rating and set a $60.00 price objective on shares of Amedisys in a research note on Friday, September 15th. BidaskClub lowered shares of Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 12th. Finally, Bank of America Corporation initiated coverage on shares of Amedisys in a research note on Monday, August 21st. They set a “neutral” rating and a $55.00 price objective for the company. Seven investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $56.20.

Amedisys (AMED) opened at 50.27 on Monday. The company’s 50-day moving average is $51.65 and its 200 day moving average is $55.05. Amedisys has a 12-month low of $34.58 and a 12-month high of $65.91. The stock has a market capitalization of $1.70 billion, a PE ratio of 42.97 and a beta of 0.87.

Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Wednesday, July 26th. The health services provider reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.50 by $0.12. The business had revenue of $378.80 million during the quarter, compared to analyst estimates of $380.80 million. Amedisys had a net margin of 2.70% and a return on equity of 13.71%. Amedisys’s revenue was up 5.0% compared to the same quarter last year. During the same period last year, the business earned $0.42 EPS. On average, equities research analysts expect that Amedisys will post $2.21 earnings per share for the current fiscal year.

WARNING: “Amedisys Inc (AMED) Given “Hold” Rating at Royal Bank Of Canada” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/23/amedisys-inc-amed-given-hold-rating-at-royal-bank-of-canada.html.

In related news, Director Bruce D. Perkins purchased 2,000 shares of the company’s stock in a transaction dated Thursday, August 3rd. The shares were purchased at an average price of $46.60 per share, with a total value of $93,200.00. Following the acquisition, the director now directly owns 15,825 shares in the company, valued at approximately $737,445. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider David B. Pearce sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $50.00, for a total transaction of $50,000.00. Following the sale, the insider now directly owns 10,488 shares in the company, valued at approximately $524,400. The disclosure for this sale can be found here. Company insiders own 2.00% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of AMED. BlackRock Inc. boosted its holdings in shares of Amedisys by 2,877.7% in the first quarter. BlackRock Inc. now owns 5,676,870 shares of the health services provider’s stock worth $290,032,000 after buying an additional 5,486,225 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Amedisys by 662.7% in the second quarter. Russell Investments Group Ltd. now owns 276,808 shares of the health services provider’s stock worth $17,387,000 after buying an additional 240,513 shares during the last quarter. FMR LLC boosted its holdings in shares of Amedisys by 6.9% in the first quarter. FMR LLC now owns 2,352,632 shares of the health services provider’s stock worth $120,196,000 after buying an additional 152,632 shares during the last quarter. Balyasny Asset Management LLC purchased a new position in shares of Amedisys in the second quarter worth approximately $7,736,000. Finally, TimesSquare Capital Management LLC boosted its holdings in shares of Amedisys by 15.7% in the second quarter. TimesSquare Capital Management LLC now owns 731,670 shares of the health services provider’s stock worth $45,956,000 after buying an additional 99,380 shares during the last quarter. 96.55% of the stock is currently owned by institutional investors.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.